Source:http://linkedlifedata.com/resource/pubmed/id/18723724
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2008-8-25
|
pubmed:abstractText |
Cholestyramine carries a risk of hyperchloraemic metabolic acidosis. Being cognisant of this drug-induced adverse event may reduce diagnostic delays. Emergency physicians should be alert about this condition, in particular among patients with pre-existing chronic kidney disease, or who are taking spironolactone.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1472-0213
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
613
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading | |
pubmed:year |
2008
|
pubmed:articleTitle |
Hyperchloraemic metabolic acidosis.
|
pubmed:affiliation |
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, SAR, China.
|
pubmed:publicationType |
Journal Article,
Case Reports
|